- Home
- PBPB vs DCTH Comparison
PBPB vs DCTH Comparison
Compare PBPB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- DCTH
- Stock Information
- Founded
- PBPB 1977
- DCTH 1988
- Country
- PBPB United States
- DCTH United States
- Employees
- PBPB N/A
- DCTH N/A
- Industry
- PBPB Restaurants
- DCTH Medical/Dental Instruments
- Sector
- PBPB Consumer Discretionary
- DCTH Health Care
- Exchange
- PBPB Nasdaq
- DCTH Nasdaq
- Market Cap
- PBPB 313.6M
- DCTH 379.5M
- IPO Year
- PBPB 2013
- DCTH N/A
- Fundamental
- Price
- PBPB $9.97
- DCTH $11.80
- Analyst Decision
- PBPB Strong Buy
- DCTH Strong Buy
- Analyst Count
- PBPB 3
- DCTH 4
- Target Price
- PBPB $15.67
- DCTH $21.50
- AVG Volume (30 Days)
- PBPB 106.7K
- DCTH 389.0K
- Earning Date
- PBPB 11-07-2024
- DCTH 11-08-2024
- Dividend Yield
- PBPB N/A
- DCTH N/A
- EPS Growth
- PBPB 641.95
- DCTH N/A
- EPS
- PBPB 1.25
- DCTH N/A
- Revenue
- PBPB $471,719,000.00
- DCTH $22,644,000.00
- Revenue This Year
- PBPB N/A
- DCTH $1,605.13
- Revenue Next Year
- PBPB $3.71
- DCTH $111.67
- P/E Ratio
- PBPB $7.90
- DCTH N/A
- Revenue Growth
- PBPB N/A
- DCTH 945.91
- 52 Week Low
- PBPB $6.28
- DCTH $3.10
- 52 Week High
- PBPB $14.36
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- PBPB 55.38
- DCTH 58.11
- Support Level
- PBPB $9.69
- DCTH $11.48
- Resistance Level
- PBPB $10.64
- DCTH $12.10
- Average True Range (ATR)
- PBPB 0.27
- DCTH 0.70
- MACD
- PBPB -0.11
- DCTH 0.07
- Stochastic Oscillator
- PBPB 29.47
- DCTH 71.39
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.